Legend Biotech Corp. LEGN, +6.39% shares gained 3.7% in premarket trading on Thursday, after the company announced that its multiple myeloma treatment Carvykti – a collaboration between Johnson & Johnson JNJ, +5.63% – generated $117 millions in sales during the second quarter. BMO Capital Markets analysts said in a Thursday research note that this represents an increase of approximately 65% over the previous quarter. They suggested that the U.S. Food and Drug Administration had increased Carvykti’s manufacturing cap. The analysts said that the latest quarterly sales “significantly increased our conviction” about Legend and J&J’s ability to ramp up Carvykti production in a relatively brief time frame and “reaffirms Carvykti’s leading position” for this type of cell therapy.